The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Panebianco, Federica ^a,b   Mazzanti, Chiara ^a,c   Tomei, Sara ^d   Aretini, Paolo ^c   Franceschi, Sara ^c   Lessi, Francesca ^c   Di Coscio, Giancarlo ^a   Bevilacqua, Generoso ^a   Marchetti, Ivo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Pisa Science Foundation   (Italy)

^d SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Computational model; Indeterminate lesions; Molecular marker; Preoperative diagnosis; Thyroid cancer

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 146B; MICRORNA 222; UNCLASSIFIED DRUG; B RAF KINASE; C8ORF4 PROTEIN, HUMAN; GENETIC MARKER; MIRN146 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; RNA; RNA, MITOCHONDRIAL; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXON; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; ONCOGENE C KIT; PATIENT CARE; PREDICTIVE VALUE; PYROSEQUENCING; TC1 GENE; THYROID CANCER; AGED; BAYES THEOREM; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETICS; MALE; METABOLISM; MIDDLE AGED; MUTATION; PRINCIPAL COMPONENT ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

AGED; BAYES THEOREM; BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PRINCIPAL COMPONENT ANALYSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RNA; ROC CURVE; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84947784206     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1917-2     Document Type: Article

References (42)

1. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8(1):83-95.
2. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest. 2010;33(5 Suppl):51-6.
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
4. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94(6):2092-8.
5. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26(1):41-4.
6. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553-9.
7. Yip L, Farris C, Kabaker AS, Hodak SP, Nikiforova MN, McCoy KL, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab. 2012;97(6):1905-12.
8. Hsiao SJ, Nikiforov YE. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer. 2014;21(5):T301-313.
9. Marchetti I, Iervasi G, Mazzanti CM, Lessi F, Tomei S, Naccarato AG, et al. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid. 2012;22(3):292-8.
10. Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009;19(8):837-42.
11. Tomei S, Mazzanti C, Marchetti I, Rossi L, Zavaglia K, Lessi F, et al. c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med. 2012;10(1):7.
12. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005;65(18):8085-9.
13. Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, et al. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat. 2004;83(1):33-42.
14. All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, et al. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci. 2004;45(7):2075-82.
15. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res. 2003;9(1):13-9.
16. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004;64(8):2898-903.
17. Tomei S, Marchetti I, Zavaglia K, Lessi F, Apollo A, Aretini P, et al. A molecular computational model improves the preoperative diagnosis of thyroid nodules. BMC Cancer. 2012;12:396.
18. Marini F, Luzi E, Brandi ML. MicroRNA Role in Thyroid Cancer Development. J Thyroid Res. 2011;2011:407123.
19. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer. 2007;43(10):1529-44.
20. Pfeffer K. Developmental and social factors in Nigerian children's accidents. Child Care Health Dev. 1991;17(6):357-65.
21. Jung Y, Bang S, Choi K, Kim E, Kim Y, Kim J, et al. TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby. Cancer Res. 2006;66(2):723-8.
22. Kim B, Koo H, Yang S, Bang S, Jung Y, Kim Y, et al. TC1(C8orf4) correlates with Wnt/beta-catenin target genes and aggressive biological behavior in gastric cancer. Clin Cancer Res. 2006;12(11 Pt 1):3541-8.
23. Yang ZQ, Moffa AB, Haddad R, Streicher KL, Ethier SP. Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways. Int J Cancer. 2007;121(6):1265-73.
24. Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP, et al. TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res. 2004;64(8):2766-73.
25. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012;18(7):2032-8.
26. Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid. 2011;21(2):111-8.
27. Chen YT, Kitabayashi N, Zhou XK, Fahey 3rd TJ, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol. 2008;21(9):1139-46.
28. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93(5):1600-8.
29. Murali R, Zarka MA, Ocal IT, Tazelaar HD. Cytologic features of epithelioid hemangioendothelioma. Am J Clin Pathol. 2011;136(5):739-46.
30. Liu YI, Kamaya A, Desser TS, Rubin DL. A bayesian network for differentiating benign from malignant thyroid nodules using sonographic and demographic features. AJR Am J Roentgenol. 2011;196(5):W598-605.
31. Needham CJ, Bradford JR, Bulpitt AJ, Westhead DR. A primer on learning in Bayesian networks for computational biology. PLoS Comput Biol. 2007;3(8):e129.
32. Chang HH, Ramoni MF. Transcriptional network classifiers. BMC Bioinform. 2009;10 Suppl 9:S1.
33. Wasserman L: All of statistics. Springer Science & Business Media, New York, 2011.
34. McLachlan G: Discriminant analysis and statistical pattern recognition, vol. 544. John Wiley & Sons, New York, 2004.
35. Hastie T, Tibshirani R, Buja A. Flexible discriminant analysis by optimal scoring. J Am Stat Assoc. 1994;89(428):1255-70.
36. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. URL http://www.R-project.org/ [Accessed 20 November 2014].
37. Cerutti JM. Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy. Curr Genomics. 2011;12(8):589-96.
38. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63(1):213-24.
39. Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab. 2013;98(1):E1-7.
40. Chua EL, Young L, Wu WM, Turtle JR, Dong Q. Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics. 2000;69(3):342-7.
41. Lugo-Reyes SO, Maldonado-Colin G, Murata C. [Artificial intelligence to assist clinical diagnosis in medicine]. Rev Alerg Mex. 2014;61(2):110-20.
42. Sargent DJ. Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer. 2001;91(8 Suppl):1636-42.